PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging. However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases. Additional markers may improve on its individual performance if they increase sensitivity and specificity and are less sensitive to other gynecologic conditions. The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125. EXPERIMENTAL DESIGN: We here validate the performance of hK11 on an independent data set and further characterize its behavior in multiple types of controls. We also investigate its behavior when combined with CA 125 to form a composite marker. hK11 had not previously been evaluated on these serum samples. CA 125, hK11, and the composite marker were evaluated for their performance in identifying ovarian cancer and for temporal stability. RESULTS: hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125. CONCLUSION: We conclude that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection.
PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging. However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases. Additional markers may improve on its individual performance if they increase sensitivity and specificity and are less sensitive to other gynecologic conditions. The humankallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125. EXPERIMENTAL DESIGN: We here validate the performance of hK11 on an independent data set and further characterize its behavior in multiple types of controls. We also investigate its behavior when combined with CA 125 to form a composite marker. hK11 had not previously been evaluated on these serum samples. CA 125, hK11, and the composite marker were evaluated for their performance in identifying ovarian cancer and for temporal stability. RESULTS:hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125. CONCLUSION: We conclude that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection.
Authors: Karen S Anderson; Jessica Wong; Allison Vitonis; Christopher P Crum; Patrick M Sluss; Joshua Labaer; Daniel Cramer Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-03 Impact factor: 4.254
Authors: Xiaocong Geng; Yueyang Liu; Tobias Dreyer; Holger Bronger; Enken Drecoll; Viktor Magdolen; Julia Dorn Journal: Am J Cancer Res Date: 2018-09-01 Impact factor: 6.166
Authors: Lynn M Amon; Wendy Law; Matthew P Fitzgibbon; Jennifer A Gross; Kathy O'Briant; Amelia Peterson; Charles Drescher; Daniel B Martin; Martin McIntosh Journal: PLoS One Date: 2010-06-15 Impact factor: 3.240
Authors: Christian M Loch; Arturo B Ramirez; Yan Liu; Cassandra L Sather; Jeffrey J Delrow; Nathalie Scholler; Barbara M Garvik; Nicole D Urban; Martin W McIntosh; Paul D Lampe Journal: Mol Oncol Date: 2007-08-30 Impact factor: 6.603
Authors: K Oikonomopoulou; L Li; Y Zheng; I Simon; R L Wolfert; D Valik; M Nekulova; M Simickova; T Frgala; E P Diamandis Journal: Br J Cancer Date: 2008-09-02 Impact factor: 7.640
Authors: F Rückert; M Hennig; C D Petraki; D Wehrum; M Distler; A Denz; M Schröder; G Dawelbait; H Kalthoff; H-D Saeger; E P Diamandis; C Pilarsky; R Grützmann Journal: Br J Cancer Date: 2008-10-14 Impact factor: 7.640